Cite
HARVARD Citation
Barco, S. et al. (2022). Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 9 (8), pp. e585-e593. [Online].